

Arjun Lakshman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1875996/publications.pdf>

Version: 2024-02-01

40
papers

1,022
citations

623188

14
h-index

433756

31
g-index

40
all docs

40
docs citations

40
times ranked

1320
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	3.3	385
2	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
3	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018, 32, 131-138.	3.3	67
4	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
5	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
6	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
7	Genomics of rare genetic diseases—experiences from India. <i>Human Genomics</i> , 2019, 13, 52.	1.4	30
8	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
9	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
10	Prevalence and Risk Factors of Hypertension among Male Occupational Bus Drivers in North Kerala, South India: A Cross-Sectional Study. <i>ISRN Preventive Medicine</i> , 2014, 2014, 1-9.	1.7	24
11	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154.	2.5	23
12	Chimeric antigen receptor T cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. <i>American Journal of Hematology</i> , 2022, 97, 99-118.	2.0	23
13	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
14	Antisynthetase syndrome: An under-recognized cause of interstitial lung disease. <i>Lung India</i> , 2016, 33, 20.	0.3	20
15	Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical) Tj ETQq1 1 0.784314 rgBT /Over Bortezomib-Based Induction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 513-519.e1.	0.2	14
16	Elevated cardiac biomarkers and echocardiographic left ventricular dysfunction at admission in patients with dengue fever: report from a tertiary care center in Northwest India. <i>Tropical Doctor</i> , 2018, 48, 261-265.	0.2	10
17	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	0.6	10
18	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	0.6	10

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8
20	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. <i>Blood</i> , 2018, 132, 3233-3233.	0.6	6
21	Miliary tuberculosis in an Indian lady: Looking beyond miliary tuberculosis. <i>Lung India</i> , 2015, 32, 492.	0.3	4
22	Knuckle Pigmentation: A Clue to Systemic Illness. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 507-508.	0.3	2
23	Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. <i>Leukemia</i> , 2018, 32, 2083-2085.	3.3	2
24	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e115-e116.	0.2	2
25	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
26	Predictive Value of Glycated Hemoglobin and Body Mass Index for Pretreatment Neuropathy in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 89-95.	0.2	1
27	A Curious Case of Sepsis. <i>Journal of Emergency Medicine</i> , 2017, 52, e61-e63.	0.3	1
28	Pachymeningeal Involvement with Blindness as the Presenting Manifestation of Non-Hodgkin Lymphoma. <i>Turkish Journal of Haematology</i> , 2018, 35, 73-74.	0.2	1
29	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. <i>Blood</i> , 2018, 132, 3303-3303.	0.6	1
30	Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma. <i>Blood</i> , 2019, 134, 5200-5200.	0.6	1
31	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8038-8038.	0.8	1
32	ECG In Evaluation for Pulmonary Thromboembolism- Occam's Razor or Hickam's Dictum?. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, OJ01.	0.8	1
33	Natural history of t(11;14) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8014-8014.	0.8	1
34	A Cutaneous Clue to a Systemic Illness. <i>Clinical Infectious Diseases</i> , 2015, 60, 1864-1865.	2.9	0
35	Hypereosinophilia in a Young Patient: Occam's Razor or Hickam's Dictum?. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 340-343.	0.3	0
36	Osteonecrosis, splenic calcification and sickle cell disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 463-464.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Cannon Ball Lung Metastases from a Previously Unreported Primary. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OJ01.	0.8	0
38	Natural history of del53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.	0.8	0
39	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
40	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0